| Recruiting | Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor NCT07171203 | University of California, San Diego | Phase 1 |
| Recruiting | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known NCT06805825 | Novelty Nobility, Inc. | Phase 1 |
| Recruiting | GIST Oral Paclitaxel(Liporaxel) NCT06326346 | Asan Medical Center | Phase 2 |
| Active Not Recruiting | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST NCT06208748 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Active Not Recruiting | Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 1 NCT06087263 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTs NCT06431451 | First Affiliated Hospital, Sun Yat-Sen University | — |
| Recruiting | Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Adv NCT06507683 | First Affiliated Hospital of Chongqing Medical University | N/A |
| Recruiting | Imatinib TDM in GIST NCT05493215 | Reema A. Patel | Phase 2 |
| Recruiting | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring NCT05500391 | Centre Oscar Lambret | Phase 2 |
| Completed | Development of a Multimodal AI System for GIST Management NCT07454967 | Qun Zhao | — |
| Recruiting | ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST NCT05366816 | University of Miami | Phase 2 |
| Recruiting | Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor NCT05905887 | Asan Medical Center | Phase 2 |
| Recruiting | The Efficacy and Safety of Temozolomide in SDH-deficient GIST NCT05661643 | Asan Medical Center | Phase 2 |
| Recruiting | Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence NCT05867901 | Peking University People's Hospital | — |
| Recruiting | A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumor NCT05938309 | Fujian Medical University | — |
| Recruiting | Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST NCT05751733 | Xiangya Hospital of Central South University | N/A |
| Recruiting | 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk NCT05385549 | Asan Medical Center | Phase 2 |
| Completed | Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real NCT05381753 | CStone Pharmaceuticals | — |
| Completed | A Drug-drug Interaction Study of Avapritinib and Midazolam NCT04908176 | Blueprint Medicines Corporation | Phase 1 |
| Recruiting | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients NCT06523582 | Universidad Nacional Autonoma de Mexico | — |
| Recruiting | Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA NCT05461664 | Xinhua Zhang, MD | — |
| Recruiting | A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal NCT05464875 | Xinhua Zhang, MD | — |
| Recruiting | Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Stu NCT05440357 | Xinhua Zhang, MD | — |
| Withdrawn | Gastrointestinal Anastomosis Using MonoPlus® Suture NCT04811833 | Aesculap AG | — |
| Unknown | Liver Transplantation for Unresectable GIST Liver Metastases NCT04825470 | Hospital Universitario Virgen de la Arrixaca | N/A |
| Unknown | Study on Integrated Nursing Strategy for Patients With Gastrointestinal Stromal Tumors After Targeted Therapy NCT05665868 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Recruiting | Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MR NCT05408897 | Peking University People's Hospital | — |
| Active Not Recruiting | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) NCT05245968 | Taiho Pharmaceutical Co., Ltd. | Phase 1 |
| Withdrawn | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) NCT05080621 | Deciphera Pharmaceuticals, LLC | Phase 1 / Phase 2 |
| Unknown | Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy NCT05132738 | RenJi Hospital | N/A |
| Completed | Study for Patients Previously Treated in Avapritinib Clinical Trials NCT04825574 | Blueprint Medicines Corporation | Phase 4 |
| Unknown | Ripretinib in Chinese Patients With Advanced GIST: a Real World Study NCT05697107 | Peking University | — |
| Unknown | 68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor NCT05001204 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Suspended | DNX-2440 for Resectable Colorectal Liver Metastasis NCT04714983 | DNAtrix, Inc. | Phase 1 |
| Completed | Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients NCT05400018 | Genetron Health | — |
| Unknown | Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach NCT05197933 | RenJi Hospital | N/A |
| Active Not Recruiting | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics NCT04584008 | Peking University | N/A |
| Terminated | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour NCT04409223 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Terminated | DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) NCT04276415 | Daiichi Sankyo | Phase 1 |
| Completed | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) NCT04282980 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 |
| Completed | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor NCT04254939 | CStone Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies NCT04000529 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Tr NCT03862768 | Shanghai Zhongshan Hospital | N/A |
| Recruiting | Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWO NCT04181970 | Grupo Espanol de Investigacion en Sarcomas | — |
| Completed | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sun NCT03944304 | Asan Medical Center | Phase 2 |
| Completed | A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Str NCT04258956 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Completed | PDR001 Plus Imatinib for Metastatic or Unresectable GIST NCT03609424 | Asan Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib NCT03673501 | Deciphera Pharmaceuticals, LLC | Phase 3 |
| Completed | A Bioequivalence Study of Sunitinib Malate Capsules. NCT05800106 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Ima NCT04106024 | Cttq | Phase 2 |
| Recruiting | Observational Registry Data on GIST Patients NCT03602092 | National Health Research Institutes, Taiwan | — |
| Active Not Recruiting | Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor ( NCT03556384 | Adam Burgoyne, MD, PhD | Phase 2 |
| Unknown | Laparoscopic Endoscopic Cooperative Surgery in the Treatment of Gastric Stromal Tumors NCT03601234 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Terminated | Epacadostat and Pembrolizumab in Patients With GIST NCT03291054 | Columbia University | Phase 2 |
| Completed | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer The NCT03353753 | Deciphera Pharmaceuticals, LLC | Phase 3 |
| Terminated | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With NCT03165721 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors NCT02232620 | Sumitomo Pharma America, Inc. | Phase 2 |
| Withdrawn | SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) NCT02342600 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Completed | MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT NCT02931929 | Medical University Innsbruck | Phase 1 / Phase 2 |
| Completed | The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib NCT02800330 | Erasmus Medical Center | Phase 4 |
| Unknown | EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs NCT02866045 | Unity Health Toronto | Phase 3 |
| Completed | Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Ima NCT02607332 | Asan Medical Center | Phase 2 |
| Completed | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST NCT02638766 | Grupo Espanol de Investigacion en Sarcomas | Phase 2 |
| Completed | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies NCT02571036 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Completed | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Suniti NCT02401815 | Cogent Biosciences, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors NCT02268435 | Asan Medical Center | Phase 1 |
| Terminated | Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST) NCT02488746 | Kliniken Ludwigsburg-Bietigheim gGmbH | — |
| Completed | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients W NCT02260505 | Centre Leon Berard | Phase 3 |
| Completed | A Real-world Comparison of FNB and FNA in IHC-required Lesions. NCT05565066 | Huazhong University of Science and Technology | — |
| Completed | The Oncopanel Pilot (TOP) Study NCT02171286 | British Columbia Cancer Agency | — |
| Unknown | A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor T NCT03092128 | Xueding Wang | — |
| Completed | Salvage Surgery for Patients With Metastatic GIST With Rego NCT04343456 | Chang Gung Memorial Hospital | — |
| Recruiting | Integrated Cancer Repository for Cancer Research NCT02012699 | University of Nebraska | — |
| Completed | Regorafenib Post-marketing Surveillance in Japan NCT01933958 | Bayer | — |
| Completed | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib NCT01863745 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor NCT01396148 | Pfizer | Phase 2 |
| Completed | Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib NCT01694277 | AB Science | Phase 3 |
| Unknown | Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT E NCT01541709 | Asan Medical Center | Phase 2 |
| Completed | Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib NCT01524848 | Scandinavian Sarcoma Group | Phase 2 |
| Completed | Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant NCT01478373 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) NCT01462994 | Technical University of Munich | Phase 3 |
| Completed | Caphosol in Oral Mucositis Due to Targeted Therapy NCT01265810 | Impaqtt Foundation | Phase 3 |
| Completed | Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 NCT01440959 | Asan Medical Center | Phase 2 |
| Completed | The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Pa NCT01421680 | Seoul National University Hospital | N/A |
| Unknown | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carci NCT01381822 | Threshold Pharmaceuticals | Phase 1 |
| Completed | Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) NCT01271712 | Bayer | Phase 3 |
| Completed | WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regoraf NCT01265979 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects NCT01270984 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Unknown | Symptom Inventory for Gastrointestinal Stromal Tumors NCT01178307 | M.D. Anderson Cancer Center | — |
| Completed | Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT NCT01151852 | Asan Medical Center | Phase 3 |
| Terminated | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors ( NCT01031628 | Sarcoma Alliance for Research through Collaboration | Phase 3 |
| Completed | Sorafenib for Imatinib/Sunitinib-failed GIST NCT01091207 | Samsung Medical Center | Phase 2 |
| Terminated | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) NCT00751036 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK NCT00976612 | Asan Medical Center | — |
| Terminated | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) NCT00812240 | AB Science | Phase 3 |
| Completed | Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitin NCT01289028 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility NCT01114087 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Ima NCT00718562 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilot NCT00756509 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least NCT00688766 | Infinity Pharmaceuticals, Inc. | Phase 3 |
| Completed | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST NCT01172548 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) NCT00782834 | Fox Chase Cancer Center | Phase 2 |
| Completed | Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tu NCT01483014 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Laparoscopic Resection of Large Gastric Stromal Tumors NCT02662478 | Medical Park Gaziantep Hospital | — |
| Completed | Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). NCT00716820 | Pfizer | — |
| Completed | Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting NCT00877045 | SCRI Development Innovations, LLC | — |
| Completed | Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo NCT00564265 | Cirujanos la Serena | — |
| Completed | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib NCT00570635 | Exelixis | Phase 2 |
| Terminated | Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients NCT00585221 | University of Utah | Phase 2 |
| Completed | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene NCT00444795 | Pfizer | — |
| Completed | Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Ha NCT00471328 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Com NCT00441155 | Novartis Pharmaceuticals | Phase 1 |
| Completed | The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). NCT00385203 | AstraZeneca | Phase 2 |
| Completed | Ph II Study of Perifosine Plus Gleevec for Patients With GIST NCT00455559 | AEterna Zentaris | Phase 2 |
| Completed | A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tert NCT00718211 | National University Hospital, Singapore | — |
| Completed | Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) NCT00276302 | Infinity Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal NCT00137449 | Pfizer | Phase 2 |
| Completed | Gastrointestinal Stromal Tumors (GIST) Registry NCT00507273 | M.D. Anderson Cancer Center | — |
| Completed | Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) NCT00135005 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) NCT00290485 | Maisonneuve-Rosemont Hospital | Phase 2 |
| Completed | Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation NCT00278876 | Asan Medical Center | Phase 2 |
| Completed | A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) NCT00457743 | Pfizer | Phase 1 / Phase 2 |
| Completed | Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastro NCT00171977 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors NCT00293124 | Central European Cooperative Oncology Group | Phase 3 |
| Completed | Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST NCT00500188 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal NCT01275222 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Exten NCT00237172 | Novartis Pharmaceuticals | Phase 2 |
| No Longer Available | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy NCT01689376 | Bayer | — |
| No Longer Available | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy NCT01646593 | Bayer | — |